Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELECTRA: Amibegron in GAD
NCT00332891Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of amibegron in generalized anxiety disorder (GAD) (4 arms), sponsored by Sanofi. Primary endpoint: Hamilton Anxiety Rating Scale Total Score at Day 56. Started Mar 2006; status: completed.
02
Drugs
amibegron
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00332891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00332891.